Imaging Mass Spectrometry of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate Tissue

Purpose: Histopathology is the standard approach for tissue diagnostics and centerpiece of pathology. Although the current system provides prognostic information, there is need for molecular markers that enhance diagnosis and better predict clinical prognosis. The ability to localize disease-specific molecular changes in biopsy tissue would help improve critical pathology decision making. Direct profiling of proteins from tissue using matrix-assisted laser desorption/ionization imaging mass spectrometry has the potential to supplement morphology with underlying molecular detail. Experimental Design: A discovery set of 11 prostate cancer (PCa)–containing and 10 benign prostate tissue sections was evaluated for protein expression differences. A separate validation set of 54 tissue sections (23 PCa and 31 benign) was used to verify the results. Cryosectioning was done to yield tissue sections analyzed by a pathologist to determine tissue morphology and mirror sections for imaging mass spectrometry. Spectra were acquired and the intensity of signals was plotted as a function of the location within the tissue. Results: An expression profile was found that discriminates between PCa and normal tissue. The overexpression of a single ion at m/z 4,355 was able to discriminate cancer from uninvolved tissue. Tandem mass spectrometry identified this marker as a fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 (MEKK2). The ability of MEKK2 to discriminate tumor from normal cells was orthogonally confirmed. Conclusions: This study highlights the potential of this approach to uncover molecular detail that can be correlated with pathology decision making. In addition, the identification of MEKK2 shows the ability to discover proteins of relevance to PCa biology. (Clin Cancer Res 2009;15(17):5541–51)

[1]  P. Chaurand,et al.  Monitoring Mouse Prostate Development by Profiling and Imaging Mass Spectrometry*S , 2008, Molecular & Cellular Proteomics.

[2]  Richard M Caprioli,et al.  Early Changes in Protein Expression Detected by Mass Spectrometry Predict Tumor Response to Molecular Therapeutics , 2004, Cancer Research.

[3]  J. Epstein,et al.  Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. , 2006, The Journal of urology.

[4]  Richard M Caprioli,et al.  Molecular imaging of thin mammalian tissue sections by mass spectrometry. , 2006, Current opinion in biotechnology.

[5]  Patrick Ducoroy,et al.  Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. , 2007, Journal of proteome research.

[6]  Gerhard Jakse,et al.  Identifying prostate carcinoma by MALDI-Imaging. , 2007, International journal of molecular medicine.

[7]  Richard J A Goodwin,et al.  Time‐dependent evolution of tissue markers by MALDI‐MS imaging , 2008, Proteomics.

[8]  Mesut Remzi,et al.  Repeat prostate biopsy: who, how and when?. a review. , 2002, European urology.

[9]  Pauline M. Rudd,et al.  Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9) , 2002, Critical reviews in biochemistry and molecular biology.

[10]  I. Fournier,et al.  Direct analysis and MALDI imaging of formalin-fixed, paraffin-embedded tissue sections. , 2007, Journal of proteome research.

[11]  D. Neal,et al.  MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion , 2003, Oncogene.

[12]  R. Caprioli,et al.  Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. , 1997, Analytical chemistry.

[13]  K. Hahn,et al.  PB1 Domain-Dependent Signaling Complex Is Required for Extracellular Signal-Regulated Kinase 5 Activation , 2006, Molecular and Cellular Biology.

[14]  G. Johnson,et al.  PB1 Domains of MEKK2 and MEKK3 Interact with the MEK5 PB1 Domain for Activation of the ERK5 Pathway* , 2003, Journal of Biological Chemistry.

[15]  Richard M Caprioli,et al.  Tissue Profiling by Mass Spectrometry , 2005, Molecular & Cellular Proteomics.

[16]  H. Hense,et al.  [Epidemiology of prostate cancer: recent results from the Epidemiological Cancer Register of the District of Münster (Germany)]. , 2008, Der Urologe. Ausg. A.

[17]  T. Noda,et al.  MALDI-based imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer liver metastasis. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  C. Tournier,et al.  A Novel Mitogen-Activated Protein Kinase Docking Site in the N Terminus of MEK5α Organizes the Components of the Extracellular Signal-Regulated Kinase 5 Signaling Pathway , 2005, Molecular and Cellular Biology.

[19]  M. Nadji,et al.  A Tissue Fixative that Protects Macromolecules (DNA, RNA, and Protein) and Histomorphology in Clinical Samples , 2003, Laboratory Investigation.

[20]  L. Egevad,et al.  Prognostic value of the Gleason score in prostate cancer , 2002, BJU international.

[21]  Yu Shyr,et al.  Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. , 2005, Cancer research.

[22]  A. Evans,et al.  Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. , 2006, The Journal of urology.

[23]  G. Johnson,et al.  MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42 , 1997, The EMBO journal.

[24]  Philip R. Cohen,et al.  Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer , 2008, Oncogene.

[25]  Richard M Caprioli,et al.  A Novel Histology-directed Strategy for MALDI-MS Tissue Profiling That Improves Throughput and Cellular Specificity in Human Breast Cancer* , 2006, Molecular & Cellular Proteomics.

[26]  B. Cuevas,et al.  Wiring diagrams of MAPK regulation by MEKK1, 2, and 3. , 2004, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[27]  P. Chaurand,et al.  Imaging mass spectrometry of intact proteins from alcohol-preserved tissue specimens: bypassing formalin fixation. , 2008, Journal of proteome research.

[28]  J. Epstein,et al.  Patient and urologist driven second opinion of prostate needle biopsies. , 2005, The Journal of urology.

[29]  Matthew J Hayat,et al.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. , 2007, The oncologist.

[30]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[31]  Anthony V D'Amico,et al.  The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate. , 2004, Urologic oncology.

[32]  Bill C. White,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[33]  Roy A Jensen,et al.  Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. , 2004, The American journal of pathology.